Clinical Trial Update: A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of MIL62 for neuromyelitis optica spectrum disorder is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 3 | Status: ACTIVE_NOT_RECRUITING